The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.

Described herein are kits, compositions, and combination therapies comprising sulindac for use in the treatment of fragile X syndrome (FXS).

Described herein are kits, compositions, and combination therapies comprising sulindac for use in the treatment of fragile X syndrome (FXS).

Nanoparticles comprising resiniferatoxin (RTX) encapsulated in a poly(lactic-co-glycolic acid) (PLGA) polymer and compositions, especially topical compositions, comprising the nanoparticles. The compositions can be used as topical formulations for ameliorating pain, including for diabetic patients with peripheral neuropathy.

Nanoparticles comprising resiniferatoxin (RTX) encapsulated in a poly(lactic-co-glycolic acid) (PLGA) polymer and compositions, especially topical compositions, comprising the nanoparticles. The compositions can be used as topical formulations for ameliorating pain, including for diabetic patients with peripheral neuropathy.

A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.

A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.

A fractionation method, pure active compounds and derivatives thereof, compositions including the same and methods of treating cancer including administering such compounds, derivatives, compositions or any combination thereof. A fractionation method of a Cyathus striatus CBS 126585 for obtaining at least one of the pure active ingredients Striatal C, Striatal C′ or Striatal D, wherein the fractionation method includes: providing an octadecyl silica gel column; and performing a series of RP-18 preparative chromatography steps using the acetadecyl silica gel column.

A fractionation method, pure active compounds and derivatives thereof, compositions including the same and methods of treating cancer including administering such compounds, derivatives, compositions or any combination thereof. A fractionation method of a Cyathus striatus CBS 126585 for obtaining at least one of the pure active ingredients Striatal C, Striatal C′ or Striatal D, wherein the fractionation method includes: providing an octadecyl silica gel column; and performing a series of RP-18 preparative chromatography steps using the acetadecyl silica gel column.

A fractionation method, pure active compounds and derivatives thereof, compositions including the same and methods of treating cancer including administering such compounds, derivatives, compositions or any combination thereof. A fractionation method of a Cyathus striatus CBS 126585 for obtaining at least one of the pure active ingredients Striatal C, Striatal C′ or Striatal D, wherein the fractionation method includes: providing an octadecyl silica gel column; and performing a series of RP-18 preparative chromatography steps using the acetadecyl silica gel column.